474 related articles for article (PubMed ID: 19877974)
1. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Spencer TJ; Greenbaum M; Ginsberg LD; Murphy WR
J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974
[TBL] [Abstract][Full Text] [Related]
2. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
[TBL] [Abstract][Full Text] [Related]
3. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
Findling RL; McBurnett K; White C; Youcha S
J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):245-52. PubMed ID: 24945085
[TBL] [Abstract][Full Text] [Related]
4. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Childress AC
Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Sallee FR; Lyne A; Wigal T; McGough JJ
J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):215-26. PubMed ID: 19519256
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Wilens TE; Robertson B; Sikirica V; Harper L; Young JL; Bloomfield R; Lyne A; Rynkowski G; Cutler AJ
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
[TBL] [Abstract][Full Text] [Related]
8. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
Cutler AJ; Brams M; Bukstein O; Mattingly G; McBurnett K; White C; Rubin J
J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
[TBL] [Abstract][Full Text] [Related]
9. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
[TBL] [Abstract][Full Text] [Related]
10. Morning and Evening Effects of Guanfacine Extended Release Adjunctive to Psychostimulants in Pediatric ADHD.
Wilens TE; McBurnett K; Turnbow J; Rugino T; White C; Youcha S
J Atten Disord; 2017 Jan; 21(2):110-119. PubMed ID: 24071772
[TBL] [Abstract][Full Text] [Related]
11. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
12. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
Connor DF; Findling RL; Kollins SH; Sallee F; López FA; Lyne A; Tremblay G
CNS Drugs; 2010 Sep; 24(9):755-68. PubMed ID: 20806988
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
14. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
[TBL] [Abstract][Full Text] [Related]
16. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
Lachaine J; Sikirica V; Mathurin K
BMC Psychiatry; 2016 Jan; 16():11. PubMed ID: 26774811
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
Iwanami A; Saito K; Fujiwara M; Okutsu D; Ichikawa H
J Clin Psychiatry; 2020 Apr; 81(3):. PubMed ID: 32297719
[TBL] [Abstract][Full Text] [Related]
18. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
Kollins SH; López FA; Vince BD; Turnbow JM; Farrand K; Lyne A; Wigal SB; Roth T
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
Sikirica V; Findling RL; Signorovitch J; Erder MH; Dammerman R; Hodgkins P; Lu M; Xie J; Wu EQ
CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
